

JOB OFFER		
REFERENCE	OPENING DATE	DEADLINE
2021.360	29/11/2023	08/12/2023
PROFILE REQUIREMENTS		
EXCLUSIVE REQUIREMENTS: (1)		
ACADEMIC DEGREE	Specialist in Clinical Pharmacology (<i>Exclusive requirement: justification must be provided with the application</i>).	
VALUED MERITS /SKYLLS		
EXPERIENCE	<ul style="list-style-type: none"> - Database management - Experience in monitoring and data management in clinical trials, especially in early trials. - Experience in design and implementation of research projects. - Experience working in multidisciplinary biomedical research groups. - Experience advising and contributing to the training of technical staff of the group. 	
LANGUAGES	-English	
CONTRACT INFORMATION		
TYPE OF CONTRACT	EXPECTED INCORPORATION DATE	JOB STATUS
Indefinite in accordance with Article 23 Bis of Law 14/2011, of June 1, 2011, on Science, Technology and Innovation.	December 2023/January 2024	Full-time 1800 hours per year (approx. 40 h/week)
ANNUAL GROSS SALARY		DURATION OF THE CONTRACT
49.134,15 €		Indefinite, linked to the duration of the project and economic availability based on RDL8/2022
WORK LOCATIONS		UNIT/DEPARTMENT
Valdecilla South Building, 2nd Floor, Oncology Clinic		Medical Oncology Service. HUMV
JOB DETAILS		
OFFER DESCRIPTION		
Research support technician		
FUNCTIONS		
<ul style="list-style-type: none"> • Collection of data from medical records, obtaining informed consent. • Management of databases for statistical analysis. • Analysis of results • Manuscript writing in English • Assessment of patient inclusion criteria for inclusion in the trial. • Assessment of toxicities and dose adjustment • Elaboration of protocols for administration and management of investigational products. • Support in monitoring, pharmacovigilance and data collection. Resolution of doubts of the monitoring staff • Communication with the international team to solve incidences. 		
PRINCIPAL INVESTIGATOR / RESPONSABLE	RESEARCH GROUP	RESEARCH PROJECT
Fernando Rivera Herrero	Ensayos clínicos, Oncología Médica y Medicina paliativa	2023.123: A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF BOTENSILIMAB (AGEN1181) Estudio de fase 2, aleatorizado y abierto de botensilimab (AGEN1181) en monoterapia y en combinación con balstilimab (AGEN2034) o con el tratamiento de referencia elegido por

		<p>el investigador (regorafenib o trifluridina y tipiracilo) para el tratamiento del cáncer colorrectal metastásico resistente. / AS MONOTHERAPY AND IN COMBINATION WITH BALSTILIMAB (AGEN2034) OR INVESTIGATOR'S CHOICE STANDARD OF CARE (REGORAFENIB OR TRIFLURIDINE AND TIPIRACIL) FOR THE TREATMENT OF REFRACTORY METASTATIC COLORECTAL CANCER.</p>		
RECRUITMENT INFORMATION				
SELECTION PROCESS STAGES (2)				EMPLOYMENT EXCHANGE
<p>1. Pre-selection 2. Interview: Minimum score for this phase: 45. 3. Report of the Selection Board 4. Resolution</p>				NOT
SELECTION BOARD				
<ul style="list-style-type: none"> • Fernando Rivera Herrero, Project's Main Researcher • Galo Peralta, IDIVAL's Management Director • Patricia Álvarez-Ingelmo, IDIVAL Human Resources Coordinator (She will act as registrar of the selection board). 				
VALUATION OF MERITS				
MERITS	EVALUATION	SCORE		MAXIMUM
Database management	Curriculum	Merit fulfillment	Yes/ Not	5
Experience in monitoring and data management in clinical trials, especially in early trials.	Curriculum	Merit fulfillment	Yes/ Not	5
Experience in design and implementation of research projects.	Curriculum	Merit fulfillment	Yes/ Not	10
Experience working in multidisciplinary biomedical research groups.	Curriculum	Merit fulfillment	Yes/ Not	20
Experience advising and contributing to the training of technical staff of the group.	Curriculum	Merit fulfillment	Yes/ Not	15
Inglés	Curriculum	Merit fulfillment	B1: 2 points B2 or more: 5 points	5
FINAL SCORE				
MAXIMUM TOTAL SCORE BY MERITS				60
MAXIMUM TOTAL SCORE IN INTERVIEW				40
MAXIMUM TOTAL SCORE				100

(1) Not subsanable

(2) See duration of each phase in the document "Selection Process"

In compliance with the provisions of Article 11 of Organic Law 3/2018, you are informed that the person responsible for the processing of your personal data is the MARQUES DE VALDECILLA INSTITUTE OF INVESTIGATION FOUNDATION (IDIVAL), your data will be treated in order to be treated to the extent that they were necessary or convenient for the development of the legal relationship established between the parties. You can exercise your rights of access, rectification, deletion, opposition, portability or limitation of the treatment, by contacting the IDIVAL FOUNDATION at the following address: AVDA. CARDENAL HERRERA ORIA, S / N 39007, SANTANDER. More information at www.idival.org/es/Política-de-Privacidad

